01—Abstract
Summary
Summary of the 8-K filed October 13, 2026. Cited figures are marked; the original filing is the authoritative source.
BridgeBio Pharma, Inc. (Nasdaq: BBIO) filed this Form 8-K on October 13, 2026, under Item 8.01 (Other Events) to furnish a press release dated October 6, 2026.
The press release announces that the FDA accepted for filing the company's New Drug Application (NDA) for oral infigratinib for the treatment of children with achondroplasia, granted Priority Review, and assigned a PDUFA target action date of February 4, 2027. BridgeBio says it is prepared to launch oral infigratinib in the U.S. upon approval. The company cites PROPEL 3, its global Phase 3 pivotal study, which met its primary endpoint of change from baseline in annualized height velocity at Week 52 (mean treatment difference of +2.10 cm/year; p<0.0001) and its key secondary endpoint of change in height Z-score (p<0.0001).
The release also reports statistically significant improvements in arm span (z-score +0.37 SD, p<0.0001) and body proportionality (mean difference of -0.05 in ages 3-8, p<0.05, described as a pre-specified exploratory analysis), along with favorable exploratory trends in sleep apnea and otitis media events. The company states that oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug. The data were published in The New England Journal of Medicine and presented at the International Congress of Children's Bone Health 2026.
The filing also notes that oral infigratinib holds Breakthrough Therapy Designation, Orphan Drug, Fast Track and Rare Pediatric Disease Designations from the FDA, and Orphan Drug Designation from the EMA. BridgeBio intends to submit a Marketing Authorization Application to the European Medicines Agency in the fourth quarter of 2026. The forward-looking statements caution that trial results, regulatory timing, and approval are uncertain.
02—Key points
Key Highlights
- FDA accepted the NDA for oral infigratinib for children with achondroplasia and granted Priority Review, with a PDUFA target action date of February 4, 2027.
- PROPEL 3 met its primary endpoint: mean treatment difference of +2.10 cm/year in annualized height velocity at Week 52 (p<0.0001); LS mean difference was +1.74 cm/year.
- Key secondary endpoint of change in height Z-score met (p<0.0001).
- Statistically significant improvement in arm span z-score (+0.37 SD, p<0.0001) and in body proportionality in ages 3-8 (mean difference of -0.05, p<0.05), the latter a pre-specified exploratory analysis.
- Oral infigratinib reported as well tolerated, with no discontinuations or serious adverse events related to study drug.
- BridgeBio anticipates a U.S. launch upon approval and plans an EMA MAA submission in the fourth quarter of 2026.
- Oral infigratinib holds Breakthrough Therapy Designation from the FDA, based on the PROPEL 2 trial.
03—Questions
Frequently Asked Questions
When is the FDA decision expected for oral infigratinib?
The FDA assigned a PDUFA target action date of February 4, 2027. The filing also notes that approval by that date is not guaranteed and that the FDA may require additional data or information.
What were the main efficacy results from the PROPEL 3 study?
PROPEL 3 met its primary endpoint of change from baseline in annualized height velocity at Week 52, with a mean treatment difference of +2.10 cm/year (LS mean difference of +1.74 cm/year; p<0.0001). The key secondary endpoint of change in height Z-score was also met (p<0.0001).
Does the filing report any safety concerns?
The company states that oral infigratinib was well tolerated, with no discontinuations or serious adverse events related to study drug.
What regulatory steps and designations does oral infigratinib have?
The product holds Breakthrough Therapy Designation from the FDA, along with Orphan Drug, Fast Track, and Rare Pediatric Disease Designations for achondroplasia, and Orphan Drug Designation from the EMA. BridgeBio plans to submit an MAA to the EMA in the fourth quarter of 2026.
Are there any risks investors should consider?
The forward-looking statements warn that trial results may not be predictive of final data, that exploratory and subgroup findings may not hold in later studies, and that regulatory approval may be delayed or not granted. They also note that the product may not become the first and only approved oral therapy for achondroplasia.
04—Continue